Sunshine Biopharma Inc. — Form S-1
Filed August 28, 2026 · analyzed by the Registration Agent
S-1
— Neutral
significance 42/100
What the filing says
Sunshine Biopharma Inc. (market cap ~$7.1M) implemented a 1-for-10 reverse stock split effective June 1, 2026, combining every 10 shares of common stock into 1 share. The company simultaneously filed an S-1 registration statement to offer 25,477,133 shares of common stock post-split. Fractional shares were rounded up; authorized capital structure (3.03B total shares: 3B common, 30M preferred) remained unchanged.
Why this rating
Reverse split is routine capital restructuring. Post-split equity offering (25.5M shares) is material in absolute terms but represents typical IPO financing for a $7.1M-cap biotech. No operational change disclosed.
See more from August 28, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.